First Time Loading...

Valeo Pharma Inc
TSX:VPH

Watchlist Manager
Valeo Pharma Inc Logo
Valeo Pharma Inc
TSX:VPH
Watchlist
Price: 0.105 CAD 5% Market Closed
Updated: May 21, 2024

Valeo Pharma Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Valeo Pharma Inc
Cost of Revenue Peer Comparison

Comparables:
BHC
TH
K
GUD
EDT
CPH

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Valeo Pharma Inc
TSX:VPH
Cost of Revenue
-CA$40.8m
CAGR 3-Years
-89%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Cost of Revenue
-$2.6B
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
-2%
Theratechnologies Inc
TSX:TH
Cost of Revenue
-$20.2m
CAGR 3-Years
9%
CAGR 5-Years
-3%
CAGR 10-Years
-16%
K
Knight Therapeutics Inc
TSX:GUD
Cost of Revenue
-CA$178.6m
CAGR 3-Years
-15%
CAGR 5-Years
-144%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Cost of Revenue
-CA$1.1m
CAGR 3-Years
-20%
CAGR 5-Years
-21%
CAGR 10-Years
-2%
Cipher Pharmaceuticals Inc
TSX:CPH
Cost of Revenue
-$4.2m
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
-34%

See Also

What is Valeo Pharma Inc's Cost of Revenue?
Cost of Revenue
-40.8m CAD

Based on the financial report for Oct 31, 2023, Valeo Pharma Inc's Cost of Revenue amounts to -40.8m CAD.

What is Valeo Pharma Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-63%

Over the last year, the Cost of Revenue growth was -90%. The average annual Cost of Revenue growth rates for Valeo Pharma Inc have been -89% over the past three years , -63% over the past five years .